Summary
The publisher's Medical Devices sector report, “Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Liver Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Liver Cancer Diagnostic Tests include assays of mostly antibodies released in response to a liver cancer and cancer-causing proteins.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Reasons to Buy
The report enables you to -
The publisher's Medical Devices sector report, “Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Liver Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Liver Cancer Diagnostic Tests include assays of mostly antibodies released in response to a liver cancer and cancer-causing proteins.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Liver Cancer Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Liver Cancer Diagnostic Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment/industry
Reasons to Buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Liver Cancer Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
1 Table of Contents
3 Products under Development
4 Liver Cancer - Pipeline Products under Development by Companies
6 Liver Cancer- Recent Developments
7 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Diagnostics
- Abcodia Ltd
- AXO Science SAS
- BioMark Technologies Inc
- Bioprognos SL
- China Sky One Medical Inc
- Digna Biotech SL
- Exact Sciences Corp
- German Cancer Research Center
- Glycotest Inc
- Glympse Bio Inc
- ImCare Biotech LLC
- Imperial College London
- IntegraGen SA
- IPDx Immunoprofiling Diagnostics GmbH
- JBS Science Inc
- Matrix-Bio Inc
- MDNA Life Sciences Inc
- Medical University of South Carolina
- Medical University of Vienna
- Memorial Sloan Kettering Cancer Center
- NanoString Technologies Inc
- Northwestern University
- Numares AG
- Oncimmune (USA) LLC
- Orion Genomics LLC
- PleX Diagnostics Inc (Inactive)
- ProMIS Neurosciences Inc
- Proplex Technologies Llc
- Proteome Sciences Plc
- Roche Diagnostics International Ltd
- University of Hong Kong
- University of Louisville
- University of Rochester
- Ventana Medical Systems Inc
- Viomics Inc.
- XEPTAGEN SpA
- Ymir Genomics LLC.